This work is motivated by a problem in reconciling two quantitative ELISA tests for an antibody to an RNA virus in a situation without a gold standard and where false negatives may occur. False negatives occur when access of the antibody to the binding site is blocked. Based on the mechanism of the assay, a mixture of four bivariate normal distributions is proposed with the mixture probabilities depending on a two-stage latent model including the prevalence of the antibody in the population and the probabilities of blocking on each test. Because there is prior information on the prevalence of the antibody, and also on the probability of false negatives, a Bayesian analysis is used. The dependence between the two tests is also modeled to be consistent with the biological mechanism. Bayesian decision theory is utilized for classification. The proposed method is applied to the motivating data set to classify the data into two groups: those with and those without the antibody. Simulation studies describe the properties of the estimation and the classification. Sensitivity to the choice of the prior distribution is also addressed by simulation. The same model with two levels of latent variables is applicable in other testing procedures such as quantitative polymerase chain reaction tests where false negatives occur when there is a mutation in the primer sequence.
Introduction
In the absence of a diagnostic test with positive predictive value (PPV) and negative predictive value (NPV) extremely close to one (a gold standard), combining multiple imperfect tests to obtain a classification may be necessary [1] . Reconciling the results of two imperfect quantitative Enzyme-Linked Immunosorbent Assay (ELISA) tests is addressed here. Based on the biological mechanism underlying the tests, a parametric model is proposed with two levels of latent variables. Prior information on the prevalence of the antibodies, and the probability of false negatives on each test is easily J. ZHANG ET AL.
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samples. The results of the analysis of samples from 100 subjects each tested by two methods are presented in Section 4 along with a prior distribution based on previous data. A series of simulation studies is provided in Section 5. Section 6 is a discussion of the model's strengths and limitations. It explains how the model is also applicable to data from multiple quantitative (real time) PCRs. Appendix A gives a biological motivation for the presence of false negatives but not false positives and the background of samples in the example. Appendix B provides details of a sensitivity analysis for the motivating data set.
Statistical Model

Notation, Assumptions and Model
For the k th sample, k = 1, 2, . . . , n, and the i th test, i = 1, 2, let Y ik be the observable result. Denote the prevalence of E2 antibodies φ = Pr(X k = 1), and denote the probability of the binding site being accessible in test i (i = 1, 2) if E2 antibodies are present as φ i = Pr(X ik = 1|X k = 1). Then assuming latent variables X 1k and X 2k are independent conditional on X k = 1, the mixture proportions are:
Pr(X 1k = X 2k = 1, X k = 1) = φ 1 φ 2 φ, Pr(X 1k = X 2k = 0) = (1 − φ 1 )(1 − φ 2 )φ + (1 − φ),
Pr(X 1k = 1, X 2k = 0, X k = 1) = φ 1 (1 − φ 2 )φ, Pr(X 1k = 0, X 2k = 1, X k = 1) = (1 − φ 1 )φ 2 φ.
The unknown parameters are denoted as ψ = (φ, φ 1 , φ 2 , µ 1N , µ 2N , β 1 , β 2 , σ 
Parameter Estimation
Maximum Likelihood(ML) Estimation
The parameters ψ can be estimated by ML. The estimates (MLE) can be found using numerical optimization and an iterative approach as follows:
1. Choose a starting value for ψ 1 = (φ, φ 1 , φ 2 ) T .
2. Maximize the log-likelihood as a function of ψ 2 = (µ 1N , µ 2N , β 1 , β 2 , σ 3. Denote the results areψ 2 |ψ 1 and then maximize the log-likelihood as a function of ψ 1 for fixed ψ 2 =ψ 2 |ψ 1 . 4. Denote the results asψ 1 and use that as a starting value to repeat the steps above until the estimates converge.
Note that without the constraint that µ iP ≥ µ iN for i = 1, 2, the likelihood may be multimodal. There is a lack of identifiability without the constraint: the constraint requires high values of either test to be "positive" and low values to be "negative". See Section 6 for more discussion.
Bayesian Estimation
In the motivating data set, there is some prior information available and this is used in constructing the prior distribution in Section 4. This prior distribution incorporates the constraint that µ iP ≥ µ iN for i = 1, 2. Because of the complexity of the model, it is impossible to obtain the marginal posterior distribution for parameters analytically. The Markov Chain Monte-Carlo (MCMC) method is utilized to simulate samples from the marginal posterior distribution of each parameter. We use the software WinBUGS [18] to implement the MCMC method and use the R package R2WinBUGS [19] to call WinBUGS. Similar results were obtained from a self contained R [19] program. Code is available in Appendix C.
Statistical Decision Rule
The classification decision is chosen after observing the values of the random variables Y 1 and Y 2 and computing the posterior distribution, denoted p(ψ|data). The observed quantitative test results Y 1 and Y 2 provide information about the parameters ψ. For a new sample with test results (Z 1 , Z 2 ), let the loss of classifying this sample as negative if it is in fact positive be L 1 and the loss of classifying this sample as positive if it is negative be L 2 , as illustrated in Table 1 .
The posterior probability of E2 antibodies being present for (Z 1 , Z 2 ), P r(X = 1|Z 1 , Z 2 , data), abbreviated to P P P , is:
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Under Bayesian decision theory [21] , the risk under the negative classification is P P P · L 1 , and the risk under the positive classification is (1 − P P P ) · L 2 . The optimal Bayes decision for (Z 1 , Z 2 ) based on the observed data is therefore the one that has the smaller risk. Hence, (Z 1 , Z 2 ) is classified as positive if (1 − P P P ) · L 2 < P P P · L 1 , which is equivalent to P P P > C, where
. The value C = 0.5 corresponds to L 1 = L 2 and represents a symmetric loss of misclassification. In many applications L 1 = L 2 and any value of C between 0 and 1 can be obtained by choosing different values. For example, false negatives in disease screening may lead to no treatment and subsequently worse consequences of the disease: in this case it may be appropriate to choose L 1 > L 2 . Alternatively if the treatment subsequent to a positive result is toxic it may be appropriate to choose L 2 > L 1 .
Illustrative Example
In the motivating example, a total of 100 blood specimens obtained from HIV infected subjects were tested with each of the two tests: called the µPlate Anti-HGenv (i = 1) and M5 (i = 2) assays. The two assays are variations on the sandwich ELISA and the differences between them are explained in more detail in Appendix A. False negatives occur in both tests when the binding site of the human antibody Ab #2 to the E2 protein is blocked by MAb #1. The additional material introduced in the µPlate Anti-HGenv through the lysate may add additional noise that causes blocking. Neither test is perfect and false negatives are thought to occur approximately 10% of the time. Moreover, no commercial and validated test is available for the antibody, which means that there is no gold standard in the data.
In this example, the prevalence of the target antibodies varies between populations but the average is thought to be about 50% in HIV-infected populations based on previous studies [22, 23, 24, 25, 26, 27] , and the chance of blocking (false negatives) for each test is thought to be around 10%. Note however that these studies used imperfect tests. Based on this information, the prior distribution (prior A) is chosen as follows:
with all of the above assumed to be independent. Recall that β i = log(µ iP − µ iN ) and so µ iP > µ iN for i = 1, 2.
The observed data are plotted on the right panel in Figure 1 and the P P P for each of the 100 blood samples are Statistics in Medicine J. ZHANG ET AL. Details of the posterior distribution are in Table 2 . Appendix B also gives a sensitivity analysis using six additional prior distributions (priors B, C, D, E, F and G). 
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Simulation Studies
A simulation study, in a 4×3 factorial structure, was designed to assess the accuracy of the Bayesian classification rule developed above. The data are assumed to arise from either the mixture of four bivariate normal distributions or a similar mixture of four bivariate t distributions with 4 degrees of freedom. Skewed versions of the distributions are also used: the bivariate skew normal and skew t distributions have shape parameter −3 (right-skewed) [28] . The values of the parameters in the model are chosen to be close to the posterior means from the motivating example in Table 2 . The posterior distribution is calculated using the mixture of bivariate normal distributions. The classification under C = 0.5, 0.7 and 0.9 is implemented. Because the simulated data is generated with a known classification of each sample (gold standard), a linear discriminant analysis is also carried out; this assumes the model is a mixture of two bivariate normal distributions. The empirical measures of the diagnostic accuracy are computed based on 500 simulated data sets for each of the three Bayesian classification rules and the linear discriminant classifier.
All the analyses converge and results are summarized in Table 3 and Table 4 . Results in Table 3 , indicate that even though the linear discriminant classifier uses more information, it assumes an incorrect distribution and it generally performs worse than the Bayesian classification method. Among the three Bayesian classification rules with different cutoff values C, for any kind of data, a higher cutoff value C leads to a lower sensitivity and a higher specificity (the higher C is, the fewer samples are classified as positive). At any fixed C, the sensitivity for the t data is slightly higher than that for the normal data, while the specificity for the normal data is much greater than for the t data. This is reasonable considering that the t distribution has fatter tails, hence the true negative group has more overlap with the true positives. The PPV and NPV have similar comparisons as the specificity and sensitivity, implying that the mis-specified model tends to overestimate the PPP for the t data, and hence more samples are classified as positive. Adding the skewness to the data does not affect the performance of the classification much but Table 4 indicates that the coverage probabilities of the 95% highest posterior density intervals for some parameters is very low in many cases. Note that the parameter estimation is biased under the mis-specified model, especially for the location and scale parameters when the true underlying marginal distribution is a mixture of skew normal or t, according to Table 4 .
Discussion
In this paper, a two-level latent model is proposed, which is consistent with the biological machenism. If the data are from the assumed bivariate normal mixture distribution, or from a similar bivariate t mixture distribution, with or without skewness, the classification has a robust discriminating capability in the cases examined by simulations.
The model assumes that conditioning on the antibodies being present (X k = 1) and both binding sites being accessible (X 1k = X 2k = 1), the measurements are positively correlated. This is reasonable as they both measure the concentration of the E2 antibody in the sample. If either the antibody is absent (X k = 0), or it is present but in one of the tests the binding site is blocked, then the responses are independent. This conditional independence assumption can be criticized, but in this case seems biologically very plausible. The two tests are carried out separately on different plates, so if the antibody is present in the sample, the blocking of the binding site for one test is independent from the blocking for the other test. Therefore, the results from the two tests are independent from each other unless both binding sites are accessible and both quantitative results reflect the concentration of the antibody of interest. Conditional independence is reasonable in the other cases when one or both tests are false negatives.
In the biological mechanism, high values of a test result should correspond to "positive" classifications and low values to "negative". The constraint µ iP ≥ µ iN for i = 1, 2 is implemented by defining β i = log(µ iP − µ iN ) (i = 1, 2). Without the constraint, there is an identifiability question. Plots of profile log-likelihood of µ iN and µ iP (i = 1, 2) indicate very well the issue in the parameter estimation for the example data set. The profile likelihoods for i = 1, 2 have a ridge, symmetric Statistics in Medicine J. ZHANG ET AL. Table 3 . Empirical sensitivity (Sen),specificity (Spe), positive predictive value (PPV) and negative predictive value (NPV) of the Bayesian classification rule and the linear discriminant classifier based on 500 simulated data sets. MCSE is the Monte-Carlo standard error of the estimate. Omitting the constraint may lead to a classification that is inconsistent with the biological mechanism. The sensitivity analysis was also repeated without the constraint, and if starting value is chosen that does not satisfy the constraint, the analysis sometimes converges to a local mode at which the constraint does not hold.
The classification can also be achieved in the ML approach. Since from the ML aspect, the parameters are fixed but unknown, the PPP for each sample is estimated by the Pr(X = 1|Z 1 , Z 2 ,ψ) in the integrand of (1), whereψ are the MLE of ψ. Figure B. 3 illustrates the histogram of PPP estimated by the ML approach and the corresponding classification. The classification is exactly the same as the classification under prior G. In the model, there are twelve parameters to be estimated and the sample size of the motivating data is just 100, which is relatively small to make asymptotic inferences. The Bayesian approach is preferred here to obtain more stable estimation because there does exist some prior information on parameters such as the prevalence and the probability of false negatives.
The model is developed based on two ELISA tests for the E2 antibodies, but it can be extended easily to an arbitrary number of tests, or modified to accommodate different kinds of testing problems. For example, in a real time polymerase chain reaction (PCR) test, part of a virus genome is amplified and quantified. If a mutation occurs in that part of the genome, the primer does not detect the virus, and a false negative results. In RNA viruses especially, errors in transcription result frequently, and mutations (and hence false negatives) result.
There remain some limitations to this method. For example the sensitivity analysis of our example (Appendix B) shows that the shapes of the marginal posterior distributions are sensitive to the choice of the prior distribution, although the overall inferences and the classification do not change much .
The parametric assumption is another limitation to this method. In the model, the results from the two tests are assumed to be a mixture of multivariate normal distributions. In practice, this may not be warranted, and is hard to verify. Under a mis-specified model, it is not surprising for estimates of the parameters to be biased. For simulated data with clear separation of the four components of the mixture model, the classification appears to be quite robust. When there is a lack of separation in the four populations, the classification is much harder and appears to have a low sensitivity in the examples J. ZHANG ET AL. examined. Computation of the PPP for each sample however, may help in a classification system that includes three categories (positive/negative/indeterminate). In our example data there was some separation in the marginal distributions that led to a robust classification. A good ELISA test or PCR test, should have separation in the marginal distributions. In addition, for a different population, a different prior distribution will be needed and the parameters may be different. For example, because HIV and GBV-C share the same modes of infection, the prevalence of the E2 antibody in an HIVinfected population is high, about 50%, whereas the prevalence in the general population of blood donors is much lower, about 5%. The prior distribution on the prevalence should be different for the two populations. Caution should also be used in using prior information from one population to extrapolate to a different population in constructing the prior. It is possible that the underlying level of what is being tested for (concentration of antibody in an ELISA, or concentration of virus in a PCR) is different in different infected populations and therefore the parameters of the mixture components involving true positive measurements will differ. It may be reasonable to assume that the true negative responses on a test are similar across populations and perhaps also the probability of a false negative. Different prior distributions for different populations are easily incorporated. Different populations may share the same model structure, but with different parameter values (perhaps, for example, with a hierarchical structure between populations).
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To summarize, this method provides a reasonable method for combining the results of quantitative tests when there is no gold standard and when false negatives may occur fairly frequently, independently on each test, and the probability of a false negative does not depend on the underlying value of the quantitative variable. It provides a systematic way of combining the results so that sufficiently high values of any one test lead to a positive classification. 
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A. Details of the Motivating Example
GBV-C is a human RNA virus, not currently known to definitely cause any disease although a recent observational study suggested a potential link between GBV-C and non-Hodgkins lymphoma [29] . There is also evidence that people with HIV disease who are co-infected with GBV-C have prolonged survival [30] . In addition,one study found an association between GBV-C and response to an HIV therapy [31] . The mechanism for these mechanisms is under investigation [32, 33, 34] . At this time, there is no commercial and validated test available for GBV-C antibodies. When people with active infection (viremia) with GBV-C clear infection, antibodies develop that are directed against the viral envelope glycoprotein 2 (E2). Several Enzyme Linked Immunosorbent Assays (ELISAs) have been designed to detect the presence of E2 antibodies in human serum samples. ELISAs can be designed in several ways, but all GBV-C assays reported to date use E2 Monoclonal antibodies (MAb) which bind to the E2 protein at a specific site.
One test was developed by Roche Laboratories and is denoted the µPlate Anti-HGenv test [35] . It is a variation of a "sandwich capture assay". It uses full-length recombinant E2 protein in a Chinese Hamster Ovary (CHO) cell lysate (this contains other cellular material in addition to E2 protein). This lysate is treated with a specific murine monoclonal antibody (MAb #1) which binds to the E2 protein. MAb #1 is biotinylated and binds to the E2 in the lysate but supposedly not to the other cellular materials present. After MAb #1 is mixed with the E2, it is added to wells on a microtitre plate together with the human sample. The wells are coated with streptavidin which binds to the biotin on the MAb #1 (which has E2 protein attached). If there are GBV-C E2 antibodies in the human sample, these human antibodies (denoted as Ab #2) in Figure A .1 will bind to the E2 protein. When the plate is subseqently washed, the E2 protein-biotinylated MAb complex remains on the plate. In some samples however, the human antibodies will not bind because they are directed against the same region on E2 recognized by MAb #1 and their access is therefore blocked; blocking may also occur because of the additional cellular material in the lysate. This blocking is the mechanism for false negatives. Anti-human IgG antibodies conjugated to an enzyme are then added to the wells, which attach to Ab#2. A colorimetric substrate for the enzyme is added afterward to allow determination of the concentration of enzyme present in the well, reflecting the amount of human anti-E2 antibody. Control wells to which no human serum is added are present on each plate to measure nonspecific material that may stick to Ab #2 and give rise to background fluorescence. The ultraviolet absorbance of color in the wells is measured and compared to the fluorescence of the control wells.
A second test (denoted M5), was developed in the Stapleton laboratory [36] , and is a more common variation on the sandwich capture assay . The end result of the test is the same, as in Figure A. 1, but the procedure to get there differs from the µPlate Anti-HGenv ELISA. A murine MAb #1 specific for E2 protein is attached to microtiter plate wells. This MAb was provided by Dr. Alfred Engel, Roche Diagnostics, Penzburg, Germany. The MAb used may be the same as the MAb used in the µPlate Anti-HGenv test; however, this information is proprietary. This antibody is not biotinylated. Semi-purified recombinant E2 protein for which the C-terminal membrane spanning domain is not included is added to wells. The plate is then washed and human serum samples applied. Human antibodies against E2 (Ab #2) will bind to the E2 protein, again unless they have the same specificity as the murine capture MAb #1. Anti-Human IgG conjugated to an enzyme is added, and the colorimetric substrate to measure human IgG uses the same methods as the µPlate Anti-HGenv assay. The result of both the µPlate Anti-HGenv and the M5 test is quantitative; however, due to differences in the capture antibody, recombinant E2 protein, the quantitative results can not be directly compared. 
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B. Summary of analyses and sensitivity to the prior distribution
Six additional prior distributions, priors B, C, D, E, F and G shown in Table B .1, are also used to analyze the example data. The marginal distributions are assumed to be mutually independent, as they are in prior A. Table B 
Parameter
Prior sim <-bugs(data, inits, model.file = "model.txt", n.iter = 15000, n.chains=1, n.thin=1, n.burnin=5000, digits=5, parameters.to.save = c("phi", "phi1", "phi2", "mu1N", "mu2N", "mu1P", "mu2P", "sigma2_1N", "sigma2_2N", "sigma2_1P", "sigma2_2P", "rho","mud1","mud2"), bugs.directory = "C:/Program Files/WinBUGS14/" ) # ======================================================================== # MCMC in R # ======================================================================== library(mvtnorm) # log likelihood loglik <-function(y,para)
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